INDV vs MNKD: fair value comparison
Indivior Pharmaceuticals, Inc. and MannKind Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MNKD currently sits closer to the top of our discount ranking.
| INDV | MNKD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $34.56 | $3.98 |
| 12-month range | $23.46–$40.25 | $2.54–$6.01 |
| Sector rank | #29 of 113 Healthcare | #24 of 113 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: INDV fair value analysis · MNKD fair value analysis